Press & News

The next generation biopharmaceuticals

Press releases 2012

2012-04-27

Interim Report – January to March 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Quarter 2012.[read more]

Older press releases

2012-02-10

Year-End Report 2011

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Year-End Report for 2011.[read more]

2012-02-02

Affibody AB and Creative Antibiotics AB enter collaboration to develop targeted antibiotics.

Solna, February 2, 2012. Affibody AB today signed an agreement with Creative Antibiotics AB with the aim of developing pharmaceutical candidates targeting gram negative bacteria.[read more]

Affibodys latest Press releases

2019-09-23

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi-...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q3 (Nov. 15, 2019)

Investor information